modelN03AG01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | ValproicAcid | |
| ATC code: | N03AG01 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.15 | L |
| clearance: | 0.01 | L/kg/h |
| other parameters in model implementation | ||
Valproic acid is an antiepileptic drug (AED) used primarily for the treatment of epilepsy, bipolar disorder, and prevention of migraine headaches. It is a broad-spectrum anticonvulsant approved for use in many countries, including the US and EU.
Pharmacokinetics
Pharmacokinetic model parameters observed in healthy adult volunteers aged 18-55, both male and female, following a single oral dose.
References
Wang, WJ, et al., & Chen, F (2024). Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained-release tablets. CPT: pharmacometrics & systems pharmacology 13(9) 1554–1569. DOI:10.1002/psp4.13191 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38923247
Xu, S, et al., & Zhao, L (2018). Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 122 170–178. DOI:10.1016/j.ejps.2018.06.033 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29981400
Xu, S, et al., & Zhao, L (2018). Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. European journal of clinical pharmacology 74(5) 583–591. DOI:10.1007/s00228-018-2414-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29340733
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)